GLP-2 TZ is a dual incretin receptor agonist, combining the effects of GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide).  This dual mechanism produces enhanced weight loss, improved glucose metabolism, and superior energy utilization compared to GLP-1 analogues alone.  It supports comprehensive metabolic optimization, influencing appetite control, insulin sensitivity, lipid metabolism, and mitochondrial efficiency.

RESEARCH

GLP-2 TZ is a synthetic peptide analog formulated exclusively for in vitro research involving analog stability and structural modeling. It is intended solely for laboratory studies focused on analog stability and structural modeling. It has been studied in non-clinical environments for its potential for resisting enzymatic breakdown and enhancing receptor interaction modeling in controlled research setting.

Chemical Information:

• Molecular Formula: C187H291N45O59
• Molecular Weight: ~4113.58 g/mol
• Sequence: HAEGTFTSDVSSYLEGQAAKAibEFIAWLVKGRG-NH2 (Aib = α-aminoisobutyric acid; Lys26 acylated with C18 fatty diacid)

Research Applications:

• Structural investigation of peptide analog stability
• Modeling of receptor-ligand binding interactions in assay conditions
• Conjugation strategy comparisons in synthetic research
• Environmental degradation and preservation analysis under lab simulation

Storage and Handling:

• Store lyophilized powder at -20°C
• Once reconstituted, store at 2–8°C and use promptly
• Use aseptic handling protocols to preserve sterility

Product Specifications:

• Purity: ≥99% (HPLC Verified)
• Appearance: Lyophilized white powder
• Solubility: Soluble in bacteriostatic water

Compliance Notice:

GLP-2 TZ is FOR RESEARCH USE ONLY. It is not intended for human or veterinary use. This product has not been evaluated by the FDA and is not to be used for therapeutic, diagnostic, or clinical purposes. Any misuse of this product may violate applicable laws and regulations. By purchasing this product, buyer represents and warrants that it will be used only for in vitro research purposes.
 

Key Benefits:

• Accelerates weight loss by combining GLP-1 and GIP receptor activation
• Improves glucose regulation and insulin responsiveness
• Reduces visceral and total body fat while preserving lean muscle
• Lowers triglycerides and cholesterol, supporting cardiovascular health
• Enhances satiety and appetite regulation through dual hypothalamic pathways
• Increases energy expenditure and metabolic rate

Mechanism of Action (Simplified):

• GLP-1 receptor activation:
  • Increases insulin secretion in a glucose-dependent manner
  • Slows gastric emptying and suppresses appetite
• GIP receptor activation:
  • Improves insulin sensitivity in adipose and muscle tissue
  • Enhances glucose uptake and energy efficiency
• Dual synergy: results in superior fat oxidation, appetite suppression, and glycemic balance compared to single-pathway incretins

Applications / Possible Uses:

• Advanced obesity and metabolic-syndrome research
• Dual-pathway incretin therapy comparison studies
• Insulin-resistance and lipid-metabolism optimization protocols
• Synergistic formulations with 5-Amino-1MQ, SLU-PP-332, or AOD-9604 for full metabolic coverage

Form / Notes:

• Lyophilized vials for reconstitution
• Standard dual incretin dosing for research use